Valuation: MicroPort NeuroScientific Corporation

Market Cap 3.93B 4.59B 586M 516M 489M 441M 831M 56.15B 842M 5.85B 2.25B 28.7B 2.2B 2.15B 92.02B P/E 2026 *
16.5x
P/E 2027 * 14.4x
Enterprise Value 3.93B 4.59B 586M 516M 489M 441M 831M 56.15B 842M 5.85B 2.25B 28.7B 2.2B 2.15B 92.02B EV / Sales 2026 *
4.49x
EV / Sales 2027 * 3.89x
Free-Float
58.56%
Yield 2026 *
2.46%
Yield 2027 * 2.75%
09-23 MicroPort NeuroScientific Corporation NuWismen® Liquid Embolic Agent Enters NMPA Innovative Green Path CI
08-31 MicroPort NeuroScientific Corporation Announces Delay in the in Publication of 2026 Interim Results CI
07-30 MicroPort NeuroScientific Unit Stent System Enters Chinese Regulator's Special Review Procedure MT
06-03 MicroPort NeuroScientific Corporation Approves Final Dividend for the Year Ended 31 December 2025 CI
06-03 MicroPort NeuroScientific Corporation commences an Equity Buyback Plan for 58,503,480 shares, representing 10% of its issued share capital, under the authorization approved on June 3, 2026. CI
06-02 MicroPort NeuroScientific Corporation's Equity Buyback announced on April 28, 2026, has expired. CI
05-28 MicroPort NeuroScientific Partners With OYMotion on Brain-Computer Interface Technology; Shares Jump 5% MT
05-25 MicroPort Neuro Unit Wins US FDA Marketing Approval for Embolization System MT
05-25 Microport Neuroscientific says FDA approves Numentm Helia coil for marketing RE
04-28 MicroPort NeuroScientific Corporation commences an Equity Buyback Plan for 57,553,156 shares, representing 10% of its issued share capital., under the authorization approved on June 27, 2025. CI
04-28 Biodlink International Company Limited Announces Changes in Executives and Board Committee, Effective from 29 April 2026 CI
03-25 MicroPort NeuroScientific posts FY profit attributable RMB184.5 million RE
03-25 MicroPort NeuroScientific Corporation Proposes Final Ordinary Dividend for the Year Ended 31 December 2025, Payable on 21 August 2026 CI
1 day-3.19%
1 month-3.19%
3 months-26.24%
6 months-23.29%
Current year-25.97%
1 month 8
Extreme 8.005
8.4
Current year 8
Extreme 8.005
14.53
1 year 8
Extreme 8.005
14.53
3 years 6.21
Extreme 6.21
19.06
5 years 6.21
Extreme 6.21
26.8
10 years 6.21
Extreme 6.21
26.8
Manager TitleAgeSince
Chief Executive Officer 50 -
Director of Finance/CFO 48 2018-05-31
Chief Tech/Sci/R&D Officer 62 2023-12-31
Director TitleAgeSince
Director/Board Member 50 2020-11-01
Director/Board Member 61 2020-11-01
Director/Board Member 45 2021-11-18
Date Insider Type Main position Quantity % Market Cap. Importance
4/1/26 Other

Chief Executive Officer

247,000 0.0422%
3/31/26 Other 30,067 0.0051% -
5/6/25 Other

Director

139,000 0.0241%
Change 5-day change 1-year change 3-year change Capi.($)
-3.19%0.00%-33.81%-33.87% 584M
-1.07%-3.52%-25.45%+4.30% 175B
-0.03%-2.23%-8.33%+12.27% 111B
-0.65%+0.81%-25.45%+0.64% 107B
+0.69%-2.90%-47.25%-11.04% 75.31B
-0.91%-2.89%-2.97%+69.34% 58.7B
-0.86%-1.15%-3.61%-30.00% 49.57B
+1.53%+4.31%+15.99%+53.87% 49.27B
-1.44%+0.77%-17.66%+22.07% 42.02B
-0.57%-1.65%+28.23%-8.74% 32.69B
Average -0.61%-1.13%-12.03%+7.88% 70.12B
Weighted average by Cap. -0.40%-1.14%-15.77%+10.29%

Financials

2026 *2027 *
Net sales 874M 1.02B 130M 115M 109M 98.14M 185M 12.49B 187M 1.3B 501M 6.39B 489M 479M 20.48B 1.01B 1.18B 150M 132M 126M 113M 214M 14.42B 216M 1.5B 578M 7.37B 565M 553M 23.64B
Net income 238M 278M 35.48M 31.24M 29.6M 26.73M 50.37M 3.4B 51.02M 354M 136M 1.74B 133M 130M 5.58B 276M 323M 41.15M 36.23M 34.33M 30.99M 58.41M 3.95B 59.17M 411M 158M 2.02B 155M 151M 6.47B
Net Debt - -
Logo MicroPort NeuroScientific Corporation
MicroPort NeuroScientific Corp is a company mainly engaged in the research, development and manufacturing of neuro-interventional medical devices. The products cover three areas of cerebrovascular disease, including hemorrhagic stroke, cerebral atherosclerotic stenosis and acute ischemic stroke. The hemorrhagic stroke products mainly include NUMEN coil, NUMEN Silk three dimensional (3D) electronically detachable coil, Nufairy absorbable embolization coil and Tubridge flow-diverting stent. The intracranial atherosclerotic stenosis products mainly include APOLLO intracranial stent, Bridge vertebral artery drug-eluting stent (DES) and Diveer intracranial balloon dilatation catheter. The acute ischemic stroke products mainly include Neurohawk intracranial thrombectomy device, Tigertriever revascularization stent and WAVE-track intracranial aspiration catheter. The products also include auxiliary access devices such as Fastrack microcatheter and U-track intracranial support catheter.
Employees
-
Trader
-
Investor
Global
-
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
6.909CNY
Average target price
10.98CNY
Spread / Average Target
+58.89%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 2172 Stock